Evidence map›Paper›PMID 34403895›Full record

ArticleAccident; analysis and prevention2021

Simulated driving performance among daily and occasional cannabis users.

Ashley Brooks-Russell, Tim Brown, Kyle Friedman, Julia Wrobel, John Schwarz, Gregory Dooley, Karen A Ryall, Benjamin Steinhart, Elise Amioka, Gary Milavetz and 2 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Accident; analysis and prevention, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07176208 (Dose Ranging Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07176208 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

Dose Ranging Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults

TypeinterventionalSponsorFood and Drug Administration (FDA)Ran2025 to 2026Enrolled48ConditionsCannabis, Drug Effects, Driving PerformanceArms5 mg Dronabinol (Marinol®) + Placebo Beverage, 10 mg Dronabinol (Marinol®) + Placebo Beverage, 5 mg Dronabinol (Marinol®) + Alcohol Beverage, 10 mg Dronabinol (Marinol®) + Alcohol Beverage, Placebo Capsule + Alcohol Beverage
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cannabis and Driving in Older Adults.JAMA network open · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Observational
  18. Interpol review of toxicology 2019-2022.Forensic science international. Synergy · 2023
    Review
  19. Article
  20. Tonic Endocannabinoid Levels Modulate Retinal Signaling.International journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Ashley Brooks-RussellDepartment of Community and Behavioral Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Tim BrownNational Advanced Driving Simulator, University of Iowa, Iowa City, IA, United States.
Kyle FriedmanRocky Mountain Poison and Drug Safety, Denver Health, Denver, CO, United States.
Julia WrobelDepartment of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
John SchwarzRocky Mountain Poison and Drug Safety, Denver Health, Denver, CO, United States.
Gregory DooleyDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO, United States.
Karen A RyallRocky Mountain Poison and Drug Safety, Denver Health, Denver, CO, United States.
Benjamin SteinhartDepartment of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Elise AmiokaRocky Mountain Poison and Drug Safety, Denver Health, Denver, CO, United States.
Gary MilavetzNational Advanced Driving Simulator, University of Iowa, Iowa City, IA, United States.
George Sam WangDepartment of Pediatrics, CU School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Michael J KosnettDepartment of Medicine, CU School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States; Department of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USUniversity of Iowa · USColorado School of Public Health · USColorado State University · USDenver Health Medical Center · US

Funding

Novel approaches to assessing cannabis impaired drivingR01DA049800 · NIDA · UNIVERSITY OF COLORADO DENVER · PI BROOKS-RUSSELL, ASHLEY · 2020 to 2024
$2.6M
NIDA NIH HHS R01 DA049800
6 · The paper itself

Abstract

objectiveDaily cannabis users develop tolerance to some drug effects, but the extent to which this diminishes driving impairment is uncertain. This study compared the impact of acute cannabis use on driving performance in occasional and daily cannabis users using a driving simulator.

methodsWe used a within-subjects design to observe driving performance in adults age 25 to 45 years with different cannabis use histories. Eighty-five participants (43 males, 42 females) were included in the final analysis: 24 occasional users (1 to 2 times per week), 31 daily users and 30 non-users. A car-based driving simulator (MiniSim™, National Advanced Driving Simulator) was used to obtain two measures of driving performance, standard deviation of lateral placement (SDLP) and speed relative to posted speed limit, in simulated urban driving scenarios at baseline and 30 min after a 15 min ad libitum cannabis smoking period. Participants smoked self-supplied cannabis flower product (15% to 30% tetrahydrocannabinol (THC). Blood samples were collected before and after smoking (30 min after the start of smoking). Non-users performed the same driving scenarios before and after an equivalent rest interval. Changes in driving performance were analyzed by repeated measures general linear models.

resultsMean whole blood THC cannabinoids concentrations post smoking were use THC = 6.4 ± 5.6 ng/ml, THC-COOH = 10.9 ± 8.79 ng/mL for occasional users and THC = 36.4 ± 37.4 ng/mL, THC-COOH = 98.1 ± 90.6 ng/mL for daily users. On a scale of 0 to 100, the mean post-use score of subjective high was similar in occasional users and daily users (52.4 and 47.2, respectively). In covariate-adjusted analysis, occasional users had a significant increase in SDLP in the straight road segment from pre to post compared to non-users; non-users decreased by a mean of 1.1 cm (25.5 cm to 24.4 cm) while occasional users increased by a mean of 1.9 cm (21.7 cm to 23.6 cm; p = 0.02). Daily users also increased adjusted SDLP in straight road segments from baseline to post-use (23.2 cm to 25.0 cm), but the change relative to non-users was not statistically significant (p = 0.08). The standardized mean difference in unadjusted SDLP from baseline to post-use in the straight road segments comparing occasional users to non-users was 0.64 (95% CI 0.09 - 1.19), a statistically significant moderate increase. When occasional users were contrasted with daily users, the baseline to post changes in SDLP were not statistically significant. Daily users exhibited a mean decrease in baseline to post-use adjusted speed in straight road segments of 1.16 mph; a significant change compared to slight speed increases in the non-users and occasional users (p = 0.02 and p = 0.01, respectively).

conclusionWe observed a decrement in driving performance assessed by SDLP after acute cannabis smoking that was statistically significant only in the occasional users in comparison to the nonusers. Direct contrasts between the occasional users and daily users in SDLP were not statistically significant. Daily users drove slower after cannabis use as compared to the occasional use group and non-users. The study results do not conclusively establish that occasional users exhibit more driving impairment than daily users when both smoke cannabis ad libitum.

Indexed as

CannabisMarijuana SmokingAccidents, TrafficAdultDronabinolHumansMiddle AgedPsychomotor PerformanceDronabinolCannabis impaired drivingCannabis useDriving simulatorDrug impaired drivingDrug toleranceLateral control

Identifiers

PMID34403895
PMCPMC8409327
OpenAlexW3193564666

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.